subsequently went on to show that expression of SNAI2 is upregulated in CML patient cells as compared to normal controls and is directly upregulated by the BCR-ABL fusion oncogene that drives the majority of CML cases. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.